CytomX Therapeutics, Inc. (CTMX) vs Nuvectis Pharma, Inc. (NVCT)

A side-by-side comparison of CytomX Therapeutics, Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
CytomX Therapeutics, Inc. logo
CTMX
CytomX Therapeutics, Inc.
$557M
$2.56HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Nuvectis Pharma, Inc. logo
NVCT
Nuvectis Pharma, Inc.
$528M
$19.89HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

Total return — CTMX vs NVCT

growth of $100 · dividends reinvested · last 5y
CTMX -39.4% (-9.5%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window
Log scale — wide-divergence pair
101001kStart $1002023202420252026$61$658
CTMX NVCT

CTMX vs NVCT: by the numbers

  • •CTMX is the larger company ($557M vs $528M market cap).
  • •Both run net losses; NVCT's is the smaller (0.00% vs -435.21% net margin).

Metrics side by side

Valuation

MetricCTMXNVCT
P/S ratio30.42N/A
P/B ratio1.8458.10

Profitability

MetricCTMXNVCT
Gross margin98.63%0.00%
Operating margin-29.35%0.00%
Net margin-435.21%0.00%
ROE-26.37%-306.61%
ROIC-25.42%-317.86%

Growth (annualized)

MetricCTMXNVCT
Revenue CAGR (5Y)2.18%N/A
Total return CAGR (5Y)-12.01%N/A

Go deeper

Full CTMX analysisFull NVCT analysisInteractive comparison tool

Dig into the metrics

CytomX Therapeutics ROENuvectis Pharma ROECytomX Therapeutics operating marginNuvectis Pharma operating marginCytomX Therapeutics revenue growthNuvectis Pharma revenue growthCytomX Therapeutics free cash flowNuvectis Pharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.